Non-coding RNA molecules offer new ways to treat heart disease

A review published in Genes & Diseases highlights how RNA molecules could open new avenues for diagnosing and treating heart disease. Researchers from Shandong Second Medical University and Qingdao University examine four groups of non-coding RNAs that influence abnormal heart muscle growth, damage caused by reduced blood supply, and heart failure.

Unlike RNAs that provide instructions for making proteins, non-coding RNAs help regulate cellular activity. The review focuses on small nucleolar RNAs, PIWI-interacting RNAs, tRNA-derived small RNAs, and circular RNAs. These molecules are attracting attention as potential biomarkers and therapeutic targets beyond the better-studied microRNAs and long non-coding RNAs.

The article brings together evidence that these RNA groups can affect gene activity, protein function, cell survival, and cardiac fibrosis, the formation of scar tissue in the heart. Their effects vary: some molecules promote damage, while others appear to protect heart cells or limit harmful structural changes.
Circular RNAs receive attention because their downstream mechanisms are comparatively well characterised. They can interact with proteins or influence networks involving microRNAs and messenger RNAs, altering pathways linked to cardiac growth, inflammation, and cell death. Research into the other three RNA groups is developing, although many functional mechanisms remain uncertain.
The review describes experimental findings that illustrate therapeutic possibilities.

In mice, inhibiting a PIWI-interacting RNA called CHAPIR reduced pathological heart muscle enlargement, lessened fibrosis, and improved cardiac performance. Targeting another molecule, CFRPi, also reduced fibrosis and improved heart function in a mouse model of pressure overload.
Potential diagnostic applications are emerging alongside these treatment strategies. Studies have identified altered RNA levels in blood samples from people with heart attacks, hypertrophic cardiomyopathy, and heart failure. Such patterns could help identify disease or assess progression. Some findings suggest combining RNA measurements with established cardiac markers could improve diagnostic performance.

However, these opportunities remain under investigation. Animal results do not establish that RNA-targeted treatments will work safely in patients, and candidate biomarkers require further clinical validation. Researchers must also determine whether altered RNA levels cause disease, contribute to its progression, or simply reflect existing damage.

Developing therapies will require delivery to the heart, control of unintended effects, and assessment of toxicity and long-term safety. Understanding interactions between RNA groups will also be important.

Source:
Journal reference:

Wang, J., et al. (2026) The emerging roles of small nucleolar RNAs, piwi-interacting RNAs, tRNA-derived small RNAs, and circular RNAs in the regulation of cardiac hypertrophy, ischemic heart disease, and heart failure. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101996. https://www.sciencedirect.com/science/article/pii/S2352304225004854?via%3Dihub

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Intravenous blood thinner improves heart recovery after cardiogenic shock